Related Experiment Video
Updated: May 14, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6
Brendan Gongol1, Traci Marin, I-Chen Peng
1Biochemistry and Molecular Biology Graduate Program, and Division of Biomedical Sciences, University of California, Riverside, CA 92521-0121, USA.
Abstract:
B-cell lymphoma-6 protein (Bcl-6) is a corepressor for inflammatory mediators such as vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and -3, which function to recruit monocytes to vascular endothelial cells upon inflammation. Poly [ADP ribose] polymerase 1 (PARP-1) is proinflammatory, in part through its binding at the Bcl-6 intron 1 to suppress Bcl-6 expression. We investigated the mechanisms by which PARP-1 dissociates from the Bcl-6 intron 1, ultimately leading to attenuation of endothelial inflammation. Analysis of the PARP-1 primary sequence suggested that phosphorylation of PARP-1 Serine 177 (Ser-177) by AMP-activated protein kinase (AMPK) is responsible for the induction of Bcl-6. Our results show that AMPK activation with treatment of 5-aminoimidazole-4-carboxamide ribonucleotide, metformin, or pulsatile shear stress induces PARP-1 dissociation from the Bcl-6 intron 1, increases Bcl-6 expression, and inhibits expression of inflammatory mediators. Conversely, AMPKα suppression or knockdown produces the opposite effects. The results demonstrate an anti-infamatory pathway linking AMPK, PARP-1, and Bcl-6 in endothelial cells.
Insights
AMP-activated protein kinase (AMPK) activation triggers the dissociation of Poly [ADP ribose] polymerase 1 (PARP-1) from the Bcl-6 intron 1. This process enhances B-cell lymphoma-6 protein (Bcl-6) expression, reducing endothelial inflammation.
Area of Science:
- Molecular Biology
- Immunology
- Cardiovascular Research
Background:
- B-cell lymphoma-6 protein (Bcl-6) acts as a corepressor for inflammatory mediators involved in monocyte recruitment.
- Poly [ADP ribose] polymerase 1 (PARP-1) promotes inflammation by suppressing Bcl-6 expression through binding to its intron 1.
Purpose of the Study:
- To investigate the mechanism by which Poly [ADP ribose] polymerase 1 (PARP-1) dissociates from the Bcl-6 intron 1.
- To elucidate the role of AMP-activated protein kinase (AMPK) in regulating this dissociation and its impact on endothelial inflammation.
Main Methods:
- Analysis of Poly [ADP ribose] polymerase 1 (PARP-1) primary sequence to identify potential phosphorylation sites.
- Treatment with AMP-activated protein kinase (AMPK) activators (5-aminoimidazole-4-carboxamide ribonucleotide, metformin, pulsatile shear stress) and inhibitors.
- Assessment of Poly [ADP ribose] polymerase 1 (PARP-1) binding to Bcl-6 intron 1, Bcl-6 expression, and inflammatory mediator expression.
Main Results:
- AMPK activation by various stimuli promotes the dissociation of Poly [ADP ribose] polymerase 1 (PARP-1) from the Bcl-6 intron 1.
- This dissociation leads to increased B-cell lymphoma-6 protein (Bcl-6) expression.
- AMPK activation and subsequent Bcl-6 upregulation inhibit the expression of key inflammatory mediators, reducing endothelial inflammation.
Conclusions:
- AMP-activated protein kinase (AMPK) phosphorylation of Poly [ADP ribose] polymerase 1 (PARP-1) at Serine 177 is crucial for its dissociation from the Bcl-6 intron 1.
- A novel anti-inflammatory pathway involving AMPK, PARP-1, and Bcl-6 in endothelial cells has been identified.
- Targeting this pathway holds potential for therapeutic interventions in inflammatory conditions.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
The JAK-STAT Signaling Pathway
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades